BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

...the mRNA-based antibody against Chikungunya virus in January. Efficacy, toxicity data for Lyvgen immunotherapy mAb Lyvgen Biopharma Co. Ltd....
...company's 4-1BB agonist mAb, was efficacious in mouse models of cancer with no liver toxicity. Lyvgen...
...1; CD73 (NT5E) - Ecto-5’-nucleotidase; EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate Pharma S.A. Lyvgen Biopharma Co. Ltd. Moderna...
BioCentury | Sep 7, 2018
Emerging Company Profile

Leveraging cross-linking

...syndrome, due in part to lack of tumor selectivity. To increase selectivity for tumor cells, Lyvgen...
...an inhibitory Fc receptor (FcR), has been shown to enhance mAb agonism of co-stimulatory receptors. Lyvgen’s...
...BMY), New York, N.Y. Lyvgen Biopharma Co. Ltd., Shanghai, China Pfizer Inc. (NYSE:PFE), New York, N.Y. Sandi Wong, Staff Writer Lyvgen Biopharma Co. Ltd. CD40 Fc...
BioCentury | Jul 20, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

...Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen...
...Biotechnology (Group) Co. Ltd. (SZSE:300009) Chinese rights to its anti-PD-1 mAb SSI-361. Lyvgen Biopharma Co. Ltd., Shanghai, China Chris Lieu Lyvgen Biopharma Co. Ltd. Programmed...
BioCentury | Jul 16, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

...Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen...
...granted Anhui Anke Biotechnology (Group) Co. Ltd. (SZSE:300009) Chinese rights to its anti-PD-1 mAb SSI-361. Chris Lieu Lyvgen Biopharma Co. Ltd. Programmed...
Items per page:
1 - 4 of 4
BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

...the mRNA-based antibody against Chikungunya virus in January. Efficacy, toxicity data for Lyvgen immunotherapy mAb Lyvgen Biopharma Co. Ltd....
...company's 4-1BB agonist mAb, was efficacious in mouse models of cancer with no liver toxicity. Lyvgen...
...1; CD73 (NT5E) - Ecto-5’-nucleotidase; EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate Pharma S.A. Lyvgen Biopharma Co. Ltd. Moderna...
BioCentury | Sep 7, 2018
Emerging Company Profile

Leveraging cross-linking

...syndrome, due in part to lack of tumor selectivity. To increase selectivity for tumor cells, Lyvgen...
...an inhibitory Fc receptor (FcR), has been shown to enhance mAb agonism of co-stimulatory receptors. Lyvgen’s...
...BMY), New York, N.Y. Lyvgen Biopharma Co. Ltd., Shanghai, China Pfizer Inc. (NYSE:PFE), New York, N.Y. Sandi Wong, Staff Writer Lyvgen Biopharma Co. Ltd. CD40 Fc...
BioCentury | Jul 20, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

...Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen...
...Biotechnology (Group) Co. Ltd. (SZSE:300009) Chinese rights to its anti-PD-1 mAb SSI-361. Lyvgen Biopharma Co. Ltd., Shanghai, China Chris Lieu Lyvgen Biopharma Co. Ltd. Programmed...
BioCentury | Jul 16, 2018
Financial News

6 Dimensions leads Lyvgen's $30M series B

...Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen...
...granted Anhui Anke Biotechnology (Group) Co. Ltd. (SZSE:300009) Chinese rights to its anti-PD-1 mAb SSI-361. Chris Lieu Lyvgen Biopharma Co. Ltd. Programmed...
Items per page:
1 - 4 of 4